| scholarly article | Q13442814 |
| P50 | author | Daniela Flavia Hozbor | Q64691267 |
| P2093 | author name string | Cécile A C M van Els | |
| Bernard Metz | |||
| Claire J P Boog | |||
| Arno Aj van der Ark | |||
| Germie Pjm van den Dobbelsteen | |||
| P2860 | cites work | Bordetella pertussis, the causative agent of whooping cough, evolved from a distinct, human-associated lineage of B. bronchiseptica | Q21131623 |
| Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies | Q24522458 | ||
| SNP-based typing: a useful tool to study Bordetella pertussis populations | Q28744176 | ||
| Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans | Q29616204 | ||
| An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis | Q29618105 | ||
| Clinical practice. Pertussis--not just for kids | Q30436343 | ||
| Role of neutrophils in response to Bordetella pertussis infection in mice | Q30438786 | ||
| How to make sense of pertussis immunogenicity data | Q30665598 | ||
| Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough | Q30819553 | ||
| The role of Toll-like receptor-4 in pertussis vaccine-induced immunity | Q33337196 | ||
| Comparative genomic profiling of Dutch clinical Bordetella pertussis isolates using DNA microarrays: identification of genes absent from epidemic strains | Q33347857 | ||
| Bordetella pertussis isolates in Finland: serotype and fimbrial expression | Q33371827 | ||
| Changes in the genomic content of circulating Bordetella pertussis strains isolated from the Netherlands, Sweden, Japan and Australia: adaptive evolution or drift? | Q33526658 | ||
| T- and B-cell-mediated protection induced by novel, live attenuated pertussis vaccine in mice. Cross protection against parapertussis | Q33564283 | ||
| Bordetella pertussis strains with increased toxin production associated with pertussis resurgence | Q33628654 | ||
| Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice | Q33725151 | ||
| Comparative genomics of prevaccination and modern Bordetella pertussis strains | Q33744416 | ||
| Seroprevalence of pertussis in The Netherlands: evidence for increased circulation of Bordetella pertussis | Q33769972 | ||
| Infection of newborn piglets with Bordetella pertussis: a new model for pertussis | Q33788175 | ||
| Synergic effect of genotype changes in pertussis toxin and pertactin on adaptation to an acellular pertussis vaccine in the murine intranasal challenge model | Q33825728 | ||
| Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs | Q33856133 | ||
| Analysis of Bordetella pertussis populations in European countries with different vaccination policies | Q33856228 | ||
| Immunomodulation in the pathogenesis of Bordetella pertussis infection and disease | Q34003426 | ||
| Serum IgA responses against pertussis proteins in infected and Dutch wP or aP vaccinated children: an additional role in pertussis diagnostics | Q34081714 | ||
| Prevalence and genetic characterization of pertactin-deficient Bordetella pertussis in Japan | Q34163792 | ||
| Th2-associated local reactions to the acellular diphtheria-tetanus-pertussis vaccine in 4- to 6-year-old children | Q34194621 | ||
| Vaccination and herd immunity: what more do we know? | Q34273085 | ||
| Immunity to Bordetella pertussis. | Q34303666 | ||
| Duration of immunity against pertussis after natural infection or vaccination | Q34416409 | ||
| Antigenic variants in Bordetella pertussis strains isolated from vaccinated and unvaccinated children | Q44532487 | ||
| Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children | Q44733749 | ||
| The Pertussis Serological Potency Test. Collaborative study to evaluatereplacement of the Mouse Protection Test | Q44811484 | ||
| Sequence variation and conservation in virulence-related genes of Bordetella pertussis isolates from the UK. | Q44851132 | ||
| Newly emerging clones of Bordetella pertussis carrying prn2 and ptxP3 alleles implicated in Australian pertussis epidemic in 2008-2010. | Q45262324 | ||
| Modified intra-cerebral challenge assay for acellular pertussis vaccines: comparisons among whole cell and acellular vaccines. | Q45927278 | ||
| Adenylate cycalse toxin of Bordetella pertussis inhibits TLR-induced IRF-1 and IRF-8 activation and IL-12 production and enhances IL-10 through MAPK activation in dendritic cells | Q46653871 | ||
| Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis | Q47685168 | ||
| Investigation of an aerosol challenge model as alternative to the intracerebral mouse protection test for potency assay of whole cell pertussis vaccines | Q48961187 | ||
| A genomics-based approach to assessment of vaccine safety and immunogenicity in children. | Q50974144 | ||
| Enhanced memory B-cell immune responses after a second acellular pertussis booster vaccination in children 9 years of age. | Q50984087 | ||
| Impact of infant and preschool pertussis vaccinations on memory B-cell responses in children at 4 years of age. | Q51004736 | ||
| Attenuated Bordetella pertussis vaccine candidate BPZE1 promotes human dendritic cell CCL21-induced migration and drives a Th1/Th17 response. | Q51015773 | ||
| Identifying long-term memory B-cells in vaccinated children despite waning antibody levels specific for Bordetella pertussis proteins. | Q51025907 | ||
| Impaired long-term maintenance and function of Bordetella pertussis specific B cell memory. | Q51044704 | ||
| Th2-polarisation of cellular immune memory to neonatal pertussis vaccination. | Q51887595 | ||
| Long-term presence of memory B-cells specific for different vaccine components. | Q51889992 | ||
| Protection against Bordetella pertussis in mice in the absence of detectable circulating antibody: implications for long-term immunity in children. | Q52026710 | ||
| Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. | Q52939420 | ||
| A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis | Q56688401 | ||
| The seroepidemiology of Bordetella pertussis infection in Western Europe | Q57385777 | ||
| Cellular Immunity as a Potential Cause of Local Reactions to Booster Vaccination With Diphtheria and Tetanus Toxoids and Acellular Pertussis Antigens | Q57768906 | ||
| The host defense peptide beta-defensin 1 confers protection against Bordetella pertussis in newborn piglets | Q34492573 | ||
| A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model. | Q34738678 | ||
| STUDIES ON WHOOPING COUGH : I. TYPE-SPECIFIC (S) AND DISSOCIATION (R) FORMS OF HEMOPHILUS PERTUSSIS. | Q35010161 | ||
| Fast, antigen-saving multiplex immunoassay to determine levels and avidity of mouse serum antibodies to pertussis, diphtheria, and tetanus antigens | Q35066267 | ||
| Systems biology of vaccination for seasonal influenza in humans | Q35118722 | ||
| Strain variation among Bordetella pertussis isolates from Québec and Alberta provinces of Canada from 1985 to 1994 | Q35155957 | ||
| Laboratory adaptation of Bordetella pertussis is associated with the loss of type three secretion system functionality | Q35191908 | ||
| Toxicity and potency evaluation of pertussis vaccines | Q35648263 | ||
| Nonhuman primate model of pertussis | Q35867565 | ||
| Bordetella pertussis strains circulating in Europe in 1999 to 2004 as determined by pulsed-field gel electrophoresis. | Q36098742 | ||
| Epidemiology of pertussis | Q36118044 | ||
| Are vaccination programs and isolate polymorphism linked to pertussis re-emergence? | Q36284571 | ||
| What is new in pertussis? | Q36296318 | ||
| Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussi | Q36369855 | ||
| Protective immunity to Bordetella pertussis requires both B cells and CD4(+) T cells for key functions other than specific antibody production | Q36404631 | ||
| Bordetella pertussis expresses a functional type III secretion system that subverts protective innate and adaptive immune responses | Q36483610 | ||
| Is the Sequenced Bordetella pertussis strain Tohama I representative of the species? | Q36747430 | ||
| WHO working group on standardisation and control of acellular pertussis vaccines--report of a meeting held on 16-17 March 2006, St. Albans, United Kingdom. | Q36763164 | ||
| Hyperproliferation of B cells specific for a weakly immunogenic PorA in a meningococcal vaccine model | Q36933060 | ||
| The benefits of using diverse animal models for studying pertussis. | Q36962817 | ||
| Immunodominance in mouse and human CD4+ T-cell responses specific for the Bordetella pertussis virulence factor P.69 pertactin | Q37075449 | ||
| Bordetella holmesii-like organisms isolated from Massachusetts patients with pertussis-like symptoms | Q37093663 | ||
| Factors contributing to pertussis resurgence | Q37174125 | ||
| Vaccines: correlates of vaccine-induced immunity | Q37193062 | ||
| Bordetella pertussis strain variation and evolution postvaccination. | Q37524032 | ||
| Pertussis epidemiology in Argentina: trends over 2004-2007. | Q37570708 | ||
| Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogen | Q37625374 | ||
| Booster vaccinations: can immunologic memory outpace disease pathogenesis? | Q37637580 | ||
| Pertussis: a matter of immune modulation | Q37825920 | ||
| First report and detailed characterization of B. pertussis isolates not expressing Pertussis Toxin or Pertactin | Q39814748 | ||
| Antimicrobial susceptibility testing of historical and recent clinical isolates of Bordetella pertussis in the United Kingdom using the Etest method | Q39867386 | ||
| Analysis of bvgR expression in Bordetella pertussis | Q40173970 | ||
| Pertussis: increasing disease as a consequence of reducing transmission | Q40355489 | ||
| Comparative safety and immunogenicity of an acellular versus whole-cell pertussis component of diphtheria-tetanus-pertussis vaccines in Senegalese infants | Q40660357 | ||
| A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine | Q40672166 | ||
| Experimental pertussis infection in the vaccinated and unvaccinated marmoset: similarities to natural infection in the child | Q41257848 | ||
| Cellular immune responses of preterm infants after vaccination with whole-cell or acellular pertussis vaccines | Q42063850 | ||
| Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. | Q43424414 | ||
| Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1. | Q43781170 | ||
| Genomic analysis and comparison of Bordetella pertussis isolates circulating in low and high vaccine coverage areas | Q44236442 | ||
| P433 | issue | 9 | |
| P304 | page(s) | 1121-1137 | |
| P577 | publication date | 2012-09-01 | |
| P1433 | published in | Expert Review of Vaccines | Q15756339 |
| P1476 | title | Resurgence of pertussis calls for re-evaluation of pertussis animal models | |
| P478 | volume | 11 |
| Q40601631 | Adaptive immune response to whole cell pertussis vaccine reflects vaccine quality: A possible complementation to the Pertussis Serological Potency test |
| Q35928346 | Association of Vitamin D Receptor Polymorphism with Susceptibility to Symptomatic Pertussis |
| Q49822345 | Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance |
| Q40647988 | Comparative efficacy of intranasal and oral vaccines against Bordetella bronchiseptica in dogs |
| Q35197120 | Complement evasion by Bordetella pertussis: implications for improving current vaccines |
| Q40578890 | Development of vaccines against pertussis caused by Bordetella holmesii using a mouse intranasal challenge model. |
| Q37718767 | Dynamics of high-risk nonvaccine human papillomavirus types after actual vaccination scheme |
| Q37613218 | Highly differentiated human airway epithelial cells: a model to study host cell-parasite interactions in pertussis |
| Q40497346 | Immunogenicity and protective efficacy of recombinant iron superoxide dismutase protein from Bordetella pertussis in mice models |
| Q35662905 | Membrane-Pore Forming Characteristics of the Bordetella pertussis CyaA-Hemolysin Domain |
| Q34066406 | Molecular signatures of the evolving immune response in mice following a Bordetella pertussis infection. |
| Q35432326 | Pertussis prevalence and its determinants among children with persistent cough in urban Uganda |
| Q37545038 | Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the United States. |
| Q26782939 | Roads to the development of improved pertussis vaccines paved by immunology |
| Q49874383 | Screening and genomic characterization of filamentous hemagglutinin-deficient Bordetella pertussis |
| Q38245642 | The baboon model of pertussis: effective use and lessons for pertussis vaccines |
| Q35737990 | The contribution of non-human primate models to the development of human vaccines |
| Q37298594 | Vaccine chronicle in Japan |
| Q34426206 | Vaccine-preventable diseases in Europe: where do we stand? |
| Q38245631 | Whole-cell pertussis vaccine potency assays: the Kendrick test and alternative assays |
Search more.